Therapeutic effect of curcumin on ulcerative culities

INTERVENTION: cap corchomin 80 mg twice a day for three months Intervention 1: cap corchomin 80 mg twice a day for three months. Intervention 2: Placebo cap twice daily. Placebo Placebo cap twice daily Treatment ‐ Drugs CONDITION: ulcerative colitis. PRIMARY OUTCOME: CRP. Timepoint: at the begining of study, 8 week after treatment. Method of measurement: lab test. Grading scale for histological assessment of inflamation in ulcerative colitis. Timepoint: at the begining of study, 8 week after treatment. Method of measurement: biopsy and lab test. Mayo score. Timepoint: at the begining of study, 8 week after treatment. Method of measurement: questionairre. Self assessment scales for evaluating mood chracteristcs pre and post intervention. Timepoint: at the begining of study, 8 week after treatment. Method of measurement: questionairre. Serum cytokins(IFN‐?, IL‐ 12, IL‐4, IL‐10, TGF‐ß , IL‐17). Timepoint: At the begining of study, 8 week after treatment. Method of measurement: lab test. Simple clinical colitisactivity index (SCCAI) score. Timepoint: At the begining of study, 8 week after treatment. Method of measurement: questionairre. Stool calprotectin. Timepoint: At the begining of study, 8 week after treatment. Method of measurement: lab test. SECONDARY OUTCOME: Hgb. Timepoint: At onset of study, end of study (8 week after treatment). Method of measurement: lab test. Quantity of Bacteroidous family and colestridium. Timepoint: At onset of study, end of study (8 week after treatment). Method of measurement: lab test. INCLUSION CRITERIA: It’s a randomized double blind controlled trial in patients with mild to moderate ulcerative colitis which is under treatment with maximum dose of mesalamine. Patients aged between 18‐70 years old with UC, which has been approved by endoscopy, will be enrolled. Mild to moderate active UC based on “simple clinical colitisactivity index (SCCAI) score” will be defined as <5 and <12 score, respectively. subjects with history of current or in past 12 weeks use of steroids, taking anti‐TNF or cyclosporine, has Hgb<10 mg/dl or hematologic abnormalities including leukopenia, thrombocytopenia, those with impaired renal, coagulation or liver tests, subjects with positive C diff infection, pregnant patients, presence of active sepsis and nurses will be excluded from the study.